Results 91 to 100 of about 6,418,358 (332)

Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates?

open access: yesBritish Journal of Cancer, 2009
Observational epidemiological studies often include prevalent cases recruited at various times past diagnosis. This left truncation can be dealt with in non-parametric (Kaplan–Meier) and semi-parametric (Cox) time-to-event analyses, theoretically ...
Elizabeth M. Azzato   +7 more
semanticscholar   +1 more source

Data‐driven discovery of gene expression markers distinguishing pediatric acute lymphoblastic leukemia subtypes

open access: yesMolecular Oncology, EarlyView.
This study investigates gene expression differences between two major pediatric acute lymphoblastic leukemia (ALL) subtypes, B‐cell precursor ALL, and T‐cell ALL, using a data‐driven approach consisting of biostatistics and machine learning methods. Following analysis of a discovery dataset, we find a set of 14 expression markers differentiating the ...
Mona Nourbakhsh   +8 more
wiley   +1 more source

Regional Variability in Survival for Patients Diagnosed with Selected Central Nervous System Tumours in Canada

open access: yesCurrent Oncology
Canada’s decentralized healthcare system may lead to regional disparities in survival among Canadians diagnosed with central nervous system (CNS) tumours.
Yifan Wu, Emily V. Walker, Yan Yuan
doaj   +1 more source

Unraveling LINE‐1 retrotransposition in head and neck squamous cell carcinoma

open access: yesMolecular Oncology, EarlyView.
The novel RetroTest method allows the detection of L1 activation in clinical samples with low DNA input, providing global L1 activity and the identification of the L1 source element. We applied RetroTest to a real‐world cohort of HNSCC patients where we reported an early L1 activation, with more than 60% of T1 patients showing L1 activity.
Jenifer Brea‐Iglesias   +12 more
wiley   +1 more source

High-Expression of Cytoplasmic Poly (A) Binding Protein 1 (PABPC1) as a Prognostic Biomarker for Early-Stage Esophageal Squamous Cell Carcinoma

open access: yesCancer Management and Research, 2021
Jiangtao Pu,1 Tao Zhang,1 Dengguo Zhang,1 Kaiming He,1 Yonghong Chen,2 Xingwang Sun,3 Wenbo Long3 1Thoracic Surgery Department of the First Affiliated Hospital, Southwest Medical University, Sichuan, People’s Republic of China; 2Laboratory of Affiliated ...
Pu J   +6 more
doaj  

Tinnitus Among Patients With Anxiety Disorder: A Nationwide Longitudinal Study

open access: yesFrontiers in Psychiatry, 2020
ObjectivesThe association between tinnitus and anxiety disorder remains debated. We used a retrospective cohort study to investigate the relationship between anxiety disorder and tinnitus, aiming to decipher possible risk factors for tinnitus in patients
Sheue-Jane Hou   +10 more
doaj   +1 more source

Tumor clusters with divergent inflammation and human retroelement expression determine the clinical outcome of patients with serous ovarian cancer

open access: yesMolecular Oncology, EarlyView.
Analysis of treatment‐naïve high‐grade serous ovarian carcinoma (HGSOC) and control tissues for ERVs, LINE‐1 (L1), inflammation, and immune checkpoints identified five clusters with diverse patient recurrence‐free survivals. An inflammation score was calculated and correlated with retroelement expression, where one novel cluster (Triple‐I) with high ...
Laura Glossner   +6 more
wiley   +1 more source

Internal limiting membrane peel: Does it change the success rate of primary vitrectomy without belt buckle in rhegmatogenous retinal detachments?

open access: yesIndian Journal of Ophthalmology, 2019
Purpose: To compare the anatomic success of pars plana vitrectomy (PPV) after internal limiting membrane (ILM) peeling at macular area and macular plus peripapillary area versus no peeling in rhegmatogenous retinal detachments (RRD).
Prashant K Bawankule   +3 more
doaj   +1 more source

Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials [PDF]

open access: yes, 2015
Background: To analyze the efficacy and toxicity of bevacizumab on survival outcomes in recurrent ovarian cancer. Results: Bevacizumab was associated with significant improvement of PFS and OS compared with standard treatment with HRs of 0.53 (95% CI 0.
BENEDETTI PANICI, PIERLUIGI   +9 more
core   +1 more source

Home - About - Disclaimer - Privacy